Core A: Protein Sciences

项目摘要--核心A：蛋白质科学 核心A(蛋白质科学)将在三个领域为我们的项目和核心提供必要的支持：蛋白质 生产和表征、高分辨率结构确定以及工艺开发和 技术转让。核心A的蛋白质生产和表征工作，由Neil King博士和Lauren领导 卡特将利用华盛顿大学蛋白质设计研究所(IPD)的广泛设施和设备，以及 其在纳米颗粒免疫原方面的独特专业知识。严格的表征和质量控制测试将确保 提供高质量的抗原、纳米颗粒免疫原和基于蛋白质的试剂以支持 项目1(Veesler)、项目2(King)和项目3(Pulendran)的科学努力。用两种X射线确定结构 结晶学和冷冻电子显微镜将由大卫·维斯勒博士领导，并将利用最新的- 艺术和内部设施，包括密歇根大学的阿诺德和梅布尔·贝克曼冷冻-EM中心。的高分辨率结构 设计的抗原、纳米颗粒免疫原和抗原-抗体复合体将提供关键信息 指导项目2中稳定抗原和广泛保护性疫苗的迭代设计。 我们的主要候选疫苗的开发和技术转让(#年末的泛肉瘤病毒疫苗 第二年和第五年年底的泛贝塔冠状病毒疫苗)，由尼尔·金博士和劳伦·卡特领导，将 基于IPD在将以蛋白质为基础的创新药物和疫苗转化为 行业合作伙伴。IPD的一个专职团队将为全面的 技术转让套餐，将加快我们广泛保护的临床前和临床发展 冠状病毒疫苗。

PROJECT SUMMARY – CORE A: PROTEIN SCIENCES Core A (Protein Sciences) will provide essential support to our Projects and Cores in three areas: protein production and characterization, high-resolution structure determination, and process development and technology transfer. Core A’s protein production and characterization efforts, led by Dr. Neil King and Lauren Carter, will leverage the extensive facilities and equipment at UW’s Institute for Protein Design (IPD) as well as its unique expertise in nanoparticle immunogens. Rigorous characterization and quality control testing will ensure the provision of high-quality antigens, nanoparticle immunogens, and protein-based reagents to support the scientific efforts of Projects 1 (Veesler), 2 (King), and 3 (Pulendran). Structure determination by both X-ray crystallography and cryo-electron microscopy will be led by Dr. David Veesler and will make use of state-of-the- art, in-house facilities including UW’s Arnold and Mabel Beckman Cryo-EM Center. High-resolution structures of designed antigens, nanoparticle immunogens, and antigen-antibody complexes will provide critical information to guide the iterative design of stabilized antigens and broadly protective vaccines in Project 2. Process development and technology transfer of our lead vaccine candidates (a pan-sarbecovirus vaccine at the end of Year 2 and a pan-betacoronavirus vaccine at the end of Year 5), led by Dr. Neil King and Lauren Carter, will build upon the IPD’s proven track record in translating innovative protein-based medicines and vaccines to industry partners. A dedicated team at the IPD will develop the methods and documentation for a comprehensive technology transfer package that will speed preclinical and clinical development of our broadly protective coronavirus vaccines.